Kazuhisa Yoshimura

Kazuhisa Yoshimura publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Kazuhisa Yoshimura sits on this spectrum.

Kazuhisa Yoshimura D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Kazuhisa Yoshimura sits on this spectrum.

Best Publications

• SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion.

  Petra Mlcochova;Steven A Kemp;Steven A Kemp;Mahesh Shanker Dhar;Guido Papa

  1313
  Citations

• Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant

  Unknown

  738
  Citations

• Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation

  Akatsuki Saito;Takashi Irie;Rigel Suzuki;Tadashi Maemura;Tadashi Maemura

  651
  Citations

• Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike

  Unknown

  522
  Citations

• Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants

  Unknown

  466
  Citations

• Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5

  Unknown

  435
  Citations

• Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant

  Unknown

  287
  Citations

• Expression of the cystic fibrosis transmembrane conductance regulator gene in the respiratory tract of normal individuals and individuals with cystic fibrosis

  Bruce C. Trapnell;Chin-Shyan Chu;Paavo K. Paakko;Tyrone C. Banks

  277
  Citations

• A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.

  Kazuhisa Yoshimura;Ryohei Kato;Mark F. Kavlick;Aline Nguyen

  209
  Citations

• Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors

  Hiroyuki Gatanaga;Yasuhiro Suzuki;Hsinyi Tsang;Kazuhisa Yoshimura;Kazuhisa Yoshimura

  205
  Citations

• Novel Low Molecular Weight Spirodiketopiperazine Derivatives Potently Inhibit R5 HIV-1 Infection through Their Antagonistic Effects on CCR5

  Kenji Maeda;Kazuhisa Yoshimura;Shiro Shibayama;Hiromu Habashita

  197
  Citations

• Virological characteristics of SARS-CoV-2 BA.2 variant

  Unknown

  187
  Citations

• JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1

  Kazuhisa Yoshimura;Ryohei Kato;Keisuke Yusa;Mark F. Kavlick

  159
  Citations

• Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant

  Unknown

  155
  Citations

• Current status of HIV/AIDS in the ART era.

  Unknown

  154
  Citations

• Recurrent HIV‐1 Integration at the<i>BACH2</i>Locus in Resting CD4⁺T Cell Populations during Effective Highly Active Antiretroviral Therapy

  Unknown

  130
  Citations

• Syntheses of 4‘-C-Ethynyl-β-d-arabino- and 4‘-C-Ethynyl-2‘-deoxy-β-d-ribo-pentofuranosylpyrimidines and -purines and Evaluation of Their Anti-HIV Activity

  Hiroshi Ohrui;Satoru Kohgo;Kenji Kitano;Shinji Sakata

  119
  Citations

• Enhanced Exposure of Human Immunodeficiency Virus Type 1 Primary Isolate Neutralization Epitopes through Binding of CD4 Mimetic Compounds

  Kazuhisa Yoshimura;Shigeyoshi Harada;Junji Shibata;Makiko Hatada

  109
  Citations

• Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity

  J Falloon;S Piscitelli;S Vogel;B Sadler

  109
  Citations

• SOCS1 is an inducible host factor during HIV-1 infection and regulates the intracellular trafficking and stability of HIV-1 Gag

  Akihide Ryo;Naomi Tsurutani;Kenji Ohba;Ryuichiro Kimura

  104
  Citations